The development of biopharmaceutical space is how much? Based on results of some biological pharmaceutical companies last year and the future trend of some experts, industry analysts, and share.

Let's look at the biological pharmaceutical enterprise in 2017. Johnson & Johnson pharmaceutical sales break through the $36 billion mark, among them, the combination of tumor, multiple myeloma and blood cancer drugs has proven to composite business growth played a crucial role. Lilly is flat, although its investment in neuroscience and oncology, but its main diabetes. Lilly has also hoped that the new drug can help offset the lai preserved the malaise of insulin.

Merck &co. In the past year's performance is not common, its product market help Merck leading cancer immunotherapy, boost its in the lung cancer has formed a strong competitive advantage, to stimulate the rapid growth of the sales. In addition, the author learned that roche for extended from Europe to the United States, the new drug is the key to the plan.

It seems that 2017 different biological pharmacy enterprises performance, competition war also gradually opened in 2018. In order to make comprehensive planning, biopharmaceutical companies need to know about industry development trend of this year. So, for bio-pharmaceutical enterprises, what are the trends in 2018 not to be missed?

Annual 1.2018 years is expected to become the global biopharmaceutical m&a

Concrete, biopharmaceutical m&a fair rise in 2018, though probably because the volume is too low in 2017, but any growth will increase biological pharmaceutical industry mergers and acquisitions in 2018. With and encourage social capital to participate in medical system reform policy "healthy China" concept, etc, and the domestic m&a activity, drug firms in China also in overseas mergers and acquisitions faster. Insiders predict, overseas mergers and acquisitions will be more Chinese drug companies incorporated in the development strategy.

2. The trend of biological technology is affecting process end user's technical requirements and buying patterns

A hat-trick of biological pharmaceutical industry, but the process can not fully meet the demand of industry. And with the trend of biological technology to process the end user the influence of the technical requirements and buying patterns, and the technology innovation slows, biological medicine enterprise is under tremendous pressure. In order to face to face with the current situation, make the actual results, some strong leading drug companies began to establish customer-focused method of collaborative research and development of new products, small and medium-sized enterprise can also set about innovation, through the way of cooperation to change the status quo.

3. Many big drug firms was targeting Asian markets

Asian population, consumer demand, especially in China. At present, China has become the second largest pharmaceutical consumer market, and a quarter of the world medical market, many large pharmaceutical companies, such as hammer flew, Merck, Johnson and Johnson, also for the Chinese market more seriously. In order to grasp the Chinese market, the major biological pharmaceutical companies are struggling to maintain spending on research and development through innovation drive to improve product productivity.

4. Global competition is always a trend will continue to follow in 2018

Where there is a market, there is competition for biopharmaceutical this fat, "battle" is not only confined to a place, but all over the world. According to the investigation, this year is an important trend in the field of biomedical, improve production efficiency to meet the growing demand, reduce the cost in order to improve the overall quality of products.